NEW YORK--(BUSINESS WIRE)--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS – Nasdaq: CLLS), on developing immunotherapies based on gene edited CAR-T cells (UCART), today announced presentations at the Piper Jaffray 27th Annual Healthcare Conference and the Oppenheimer 26th Annual Healthcare Conference.
-
December 2, 2015 - Piper Jaffray 27th Annual Healthcare Conference -
NYC
Fireside chat presentation from 1:00pm to 1:25pm ET at the New York Palace Hotel -
December 9, 2015 - Oppenheimer 26th Annual Healthcare Conference - NYC
Company presentation from 9:10am to 9:40am ET at the Westin New York Grand Central
About Cellectis
Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it.
TALEN® is a
registered trademark owned by the Cellectis Group.
